Inhibition of MicroRNA-182/183 Cluster Ameliorates Schizophrenia by Activating the Axon Guidance Pathway and

Zhichao Wang1, Lin Su2, Tong Wu3

  • 1Department of Academic Research, Qiqihar Medical University, Qiqihar 161000, China.

Insights

Inhibiting the miR-182/183 cluster may treat schizophrenia (SZ). This microRNA cluster targets DCC, impacting axon guidance and neuronal activity, offering a potential therapeutic avenue for SZ.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Schizophrenia (SZ) is a complex disorder with genetic and environmental influences.
  • MicroRNAs (miRNAs) are increasingly implicated in SZ pathology.
  • The role of the miR-182/183 cluster in SZ remains to be fully elucidated.

Purpose of the Study:

  • To investigate the involvement of the miR-182/183 cluster in SZ.
  • To explore the underlying mechanism of the miR-182/183 cluster in SZ progression.
  • To assess the therapeutic potential of targeting the miR-182/183 cluster for SZ.

Main Methods:

  • Established rat models of SZ using MK-801 and exposed primary hippocampal neurons to MK-801.
  • Manipulated the expression of miR-182/183 and its target gene DCC in vitro and in vivo.
  • Assessed SZ-related behavioral and molecular changes, including neuronal apoptosis, serum markers, and gene expression.

Main Results:

  • miR-182 and miR-183 were highly expressed in SZ patients and rat models.
  • The miR-182/183 cluster targets DCC, downregulating its expression.
  • Inhibition of miR-182/183 ameliorated SZ symptoms and reduced neuronal apoptosis.
  • DCC activation of the axon guiding pathway influences synaptic activity.

Conclusions:

  • Inhibition of the miR-182/183 cluster attenuates SZ via DCC-dependent axon guidance pathway activation.
  • The miR-182/183 cluster represents a potential therapeutic target for schizophrenia treatment.